C4 Therapeutics Inc Cash Flow Conversion Efficiency
C4 Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, C4 Therapeutics Inc (CCCC) has a cash flow conversion efficiency ratio of -0.006x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.57 Million) by net assets ($247.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of C4 Therapeutics Inc (2018–2025)
Cash flow conversion efficiency of C4 Therapeutics Inc from 2018 to 2025. This chart illustrates how C4 Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View C4 Therapeutics Inc stock price for real-time trading data and today's change.
C4 Therapeutics Inc Cash Flow Conversion Ratio Explained
C4 Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
C4 Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of C4 Therapeutics Inc ranked by their cash flow conversion efficiency. Also see C4 Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningxia Younglight Chemicals Co Ltd
SHE:000635
|
0.008x |
|
Traffic Control Technology Co Ltd
SHG:688015
|
-0.017x |
|
Beijing Emerging Eastern Aviation Equipment Co Ltd Class A
SHE:002933
|
0.009x |
|
AdvanSix Inc
NYSE:ASIX
|
0.013x |
|
InPlay Oil Corp
TO:IPO
|
0.076x |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
-0.240x |
|
Beijing Jingyeda Technology Co Ltd
SHE:003005
|
-0.012x |
|
Shanghai Hollywave Electronic System Co. Ltd. A
SHG:688682
|
-0.012x |
Annual Cash Flow Conversion Efficiency for C4 Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of C4 Therapeutics Inc from 2018 to 2025. Review C4 Therapeutics Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $256.59 Million | $-98.69 Million | -0.385x | -27.50% |
| 2024-12-31 | $215.99 Million | $-65.16 Million | -0.302x | +30.51% |
| 2023-12-31 | $246.11 Million | $-106.84 Million | -0.434x | -18.52% |
| 2022-12-31 | $289.23 Million | $-105.94 Million | -0.366x | -64.09% |
| 2021-12-31 | $389.61 Million | $-86.97 Million | -0.223x | +6.80% |
| 2020-12-31 | $280.79 Million | $-67.25 Million | -0.239x | +51.78% |
| 2019-12-31 | $-111.96 Million | $55.61 Million | -0.497x | -333.28% |
| 2018-12-31 | $-79.75 Million | $-16.98 Million | 0.213x | -- |
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology p… Read more